Perfusion Index Variability in Preterm Infants Treated with Two Different Natural Surfactants for Respiratory Distress Syndrome

Abstract

Objective The objective of this study was to compare the perfusion index (PI) variability in premature infants with respiratory distress syndrome (RDS) following administration of two different natural surfactant preparations.

Study design This was a prospective study on 92 preterm infants with RDS. Patients were randomized into two groups. Group 1 (n = 46) received beractant; Group 2 (n = 46) received poractant alfa. Oxygen saturation, PI, and heart rate were measured by Masimo Rainbow SET Radical-7 pulse oximeter (Masimo Corp., Irvine, CA) before and after surfactant. The effects of the two treatment regimens on PI and oxygenation were compared.

Results Repeated doses were more needed in beractant group (p = 0.04). Median oxygenation index (OI) before surfactant were similar, but improvement in OI was more prominent at 6th hour of surfactant in Group 2 (p = 0.001). Both groups had similar preductal PI values before surfactant. PI was higher at 6th hour of surfactant in Group 2 (p = 0.001). Pulmonary hemorrhage, intraventricular hemorrhage, patent ductus arteriosus, necrotizing enterocolitis, and mortality were more frequent in infants whose PI values lower than 0.7 within the first 5 days of life (p = 0.001).

Conclusion Poractant alfa resulted in more prominent improvement in PI and OI. Low PI values measured at early postnatal period may predict poor clinical outcome in preterm infants with RDS.

Keywords

surfactant - respiratory distress syndrome - perfusion - pulmonary hemorrhage

• References

• 1 Jobe AH. Pulmonary surfactant therapy. N Engl J Med 1993; 328 (12) 861-868
• 2 Horbar JD, Wright LL, Soll RF , et al; National Institute of Child Health and Human Development Neonatal Research Network. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. J Pediatr 1993; 123 (5) 757-766
• 3 Salyer JW. Neonatal and pediatric pulse oximetry. Respir Care 2003; 48 (4) 386-396 , discussion 397–398
• 4 De Felice C, Latini G, Vacca P, Kopotic RJ. The pulse oximeter perfusion index as a predictor for high illness severity in neonates. Eur J Pediatr 2002; 161 (10) 561-562
• 5 Cresi F, Pelle E, Calabrese R, Costa L, Farinasso D, Silvestro L. Perfusion index variations in clinically and hemodynamically stable preterm newborns in the first week of life. Ital J Pediatr 2010; 36: 6
• 6 Granelli Ad, Ostman-Smith I. Noninvasive peripheral perfusion index as a possible tool for screening for critical left heart obstruction. Acta Paediatr 2007; 96 (10) 1455-1459
• 7 Speer CP, Gefeller O, Groneck P , et al. Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed 1995; 72 (1) F8-F13
• 8 Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K ; North American Study Group. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol 2004; 21 (3) 109-119
• 9 Liechty EA, Donovan E, Purohit D , et al. Reduction of neonatal mortality after multiple doses of bovine surfactant in low birth weight neonates with respiratory distress syndrome. Pediatrics 1991; 88 (1) 19-28
• 10 Halliday HL, Tarnow-Mordi WO, Corcoran JD, Patterson CC. Multicentre randomised trial comparing high and low dose surfactant regimens for the treatment of respiratory distress syndrome (the Curosurf 4 trial). Arch Dis Child 1993; 69 (3 Spec No): 276-280
• 11 Walsh MC, Kliegman RM, Fanaroff AA. Necrotizing enterocolitis: a practitioner's perspective. Pediatr Rev 1988; 9 (7) 219-226
• 12 Fujiwara T, Konishi M, Chida S , et al; The Surfactant-TA Study Group Surfactant replacement therapy with a single postventilatory dose of a reconstituted bovine surfactant in preterm neonates with respiratory distress syndrome: final analysis of a multicenter, double-blind, randomized trial and comparison with similar trials. Pediatrics 1990; 86 (5) 753-764
• 13 Malloy CA, Nicoski P, Muraskas JK. A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. Acta Paediatr 2005; 94 (6) 779-784
• 14 Fujii AM, Patel SM, Allen R, Doros G, Guo CY, Testa S. Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome. J Perinatol 2010; 30 (10) 665-670
• 15 Soll R, Ozek E. Multiple versus single doses of exogenous surfactant for the prevention or treatment of neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2009; (1) CD000141
• 16 Singh N, Hawley KL, Viswanathan K. Efficacy of porcine versus bovine surfactants for preterm newborns with respiratory distress syndrome: systematic review and meta-analysis. Pediatrics 2011; 128 (6) e1588-e1595
• 17 Berg TJ, Pagtakhan RD, Reed MH, Langston C, Chernick V. Bronchopulmonary dysplasia and lung rupture in hyaline membrane disease: influence of continuous distending pressure. Pediatrics 1975; 55 (1) 51-54
• 18 Raju TN, Langenberg P. Pulmonary hemorrhage and exogenous surfactant therapy: a metaanalysis. J Pediatr 1993; 123 (4) 603-610
• 19 Committee on Fetus and Newborn. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 2002; 109 (2) 330-338
• 20 Egberts J. Theoretical changes in neonatal hospitalisation costs after the introduction of porcine-derived lung surfactant ('Curosurf'). Pharmacoeconomics 1995; 8 (4) 324-342
• 21 Köksal N, Akpinar R, Cetinkaya M. Early administration of the second surfactant dose in preterm infants with severe respiratory distress syndrome. Turk J Pediatr 2009; 51 (6) 556-564
• 22 Greenough A, Roberton NR. Acute respiratory disease in the newborn. In: Roberton NR, Rennie JM, , eds. Textbook of Neonatology, 3rd ed. New York: Churchill Livingstone; 1999: 481-514
• 23 Bowen W, Martin CR, Krauss AN, Auld PA. Ventilation-perfusion relationships in preterm infants after surfactant treatment. Pediatr Pulmonol 1994; 18 (3) 155-162